November 28, 2016 - By Pete Kolinski · 0 Comments
The stock of Audentes Therapeutics Incorporated (NASDAQ:BOLD) registered an increase of 6.06% in short interest. BOLD’s total short interest was 491,600 shares in November as published by FINRA. Its up 6.06% from 463,500 shares, reported previously. With 62,700 shares average volume, it will take short sellers 8 days to cover their BOLD’s short positions. The short interest to Audentes Therapeutics Incorporated’s float is 7.18%. The stock increased 0.06% or $0.01 on November 25, hitting $17.99. Audentes Therapeutics Inc (NASDAQ:BOLD) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
Audentes Therapeutics, Inc. is a biotechnology company. The company has a market cap of $391.05 million. The Firm focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. It currently has negative earnings. The Company’s portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy ; AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
More notable recent Audentes Therapeutics Inc (NASDAQ:BOLD) news were published by: Prnewswire.com which released: “Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference” on November 21, 2016, also Prnewswire.com with their article: “Audentes Therapeutics Reports Second Quarter 2016 Financial Results and …” published on August 31, 2016, Prnewswire.com published: “Audentes Therapeutics Reports Third Quarter 2016 Financial Results and …” on November 10, 2016. More interesting news about Audentes Therapeutics Inc (NASDAQ:BOLD) were released by: Prnewswire.com and their article: “Audentes Therapeutics Announces Pricing of Initial Public Offering” published on July 20, 2016 as well as Prnewswire.com‘s news article titled: “Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference” with publication date: August 08, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski